Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025HaematologicaOpen Access

Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJaime SanzAFAllain-Thibeault FerhatAKAlexander Kulagin

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows no impact of donor matching on leukemia-free survival in ALL, suggesting donor traits matter more.

Key Points

  • Donor characteristics, not matching, influenced leukemia-free survival in patients with acute lymphoblastic leukemia.
  • The primary endpoint was leukemia-free survival (LFS), with no significant differences found between donor types.
  • Analysis included 350 ALL patients comparing 8/8 HLA-matched MUD to 7/8 HLA-matched MMUD.
  • Findings indicate prioritizing non-HLA factors may enhance donor selection strategies for ALL in transplantation.

Cite This Study

Sanz et al. (2025) studied this question.

synapsesocial.com/papers/68c23e4fb210217d64792201https://doi.org/10.3324/haematol.2025.287750
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Matched Unrelated vs Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide2025 · 7 citations
  2. 2Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT2025
  3. 3Donor‐Related Factors Affecting Haploidentical HSCT Outcomes in Acute Leukemia: A Single‐Center Retrospective Cohort Study of a Modified Combination of Anti‐Thymocyte Globulin and Post‐Transplant Cyclophosphamide2026
  4. 4Comparison of outcomes in pediatric patients with acute leukemia undergoing allogeneic HLA-haploidentical hematopoietic stem cell transplantation (HSCT) after in vitro a/b T- and CD19-cell depletion or In Vivo administration of post-transplant cyclophosphamide: An EBMT pediatric working party study2025
  5. 5Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse‐Risk <i>TP53</i>‐Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation2025 · 1 citations